These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 11742322)
1. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322 [TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives. Santen RJ Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304 [TBL] [Abstract][Full Text] [Related]
3. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. Samojlik E; Veldhuis JD; Wells SA; Santen RJ J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409 [TBL] [Abstract][Full Text] [Related]
4. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205 [TBL] [Abstract][Full Text] [Related]
5. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Poulin R; Labrie F Cancer Res; 1986 Oct; 46(10):4933-7. PubMed ID: 2944574 [TBL] [Abstract][Full Text] [Related]
6. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517 [TBL] [Abstract][Full Text] [Related]
7. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Berry J Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441 [TBL] [Abstract][Full Text] [Related]
8. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Cohen MH; Johnson JR; Li N; Chen G; Pazdur R Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893 [TBL] [Abstract][Full Text] [Related]
9. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Toth-Fejel S; Cheek J; Calhoun K; Muller P; Pommier RF Arch Surg; 2004 Jan; 139(1):50-4. PubMed ID: 14718276 [TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors in breast cancer therapy. Brueggemeier RW Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240 [TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. Calhoun KE; Pommier RF; Muller P; Fletcher WS; Toth-Fejel S Arch Surg; 2003 Aug; 138(8):879-83. PubMed ID: 12912747 [TBL] [Abstract][Full Text] [Related]
12. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182 [TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors: new endocrine treatment of breast cancer. Brueggemeier RW Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379 [TBL] [Abstract][Full Text] [Related]
14. How effective is surgical adrenalectomy in lowering steroid hormone concentrations? Worgul TJ; Santen RJ; Samojlik E; Wells SA J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336 [TBL] [Abstract][Full Text] [Related]
15. Significance of aromatase activity in human breast cancer. Miller WR; Hawkins RA; Forrest AP Cancer Res; 1982 Aug; 42(8 Suppl):3365s-3368s. PubMed ID: 7083201 [TBL] [Abstract][Full Text] [Related]
16. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Lønning PE; Geisler J; Johannessen DC; Ekse D J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198 [TBL] [Abstract][Full Text] [Related]
17. Dehydroepiandrosterone sulfate estrogenic action at its physiological plasma concentration in human breast cancer cell lines. Le Bail JC; Allen K; Nicolas JC; Habrioux G Anticancer Res; 1998; 18(3A):1683-8. PubMed ID: 9673390 [TBL] [Abstract][Full Text] [Related]
18. The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression. Calhoun K; Pommier R; Cheek J; Fletcher W; Toth-Fejel S Am J Surg; 2003 May; 185(5):411-5. PubMed ID: 12727558 [TBL] [Abstract][Full Text] [Related]
19. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679 [TBL] [Abstract][Full Text] [Related]
20. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]